


**Univ.-Prof. Dr. med. Bastian von Tresckow**  
born 15/12/1977 (m) in Marburg, Germany



### **University Hospital Essen**

Department of Hematology and Stem Cell Transplantation  
West German Cancer Center  
Cancer Research Center Cologne Essen - CCCE  
Hufelandstr. 55, D-45147 Essen  
Phone: +49 (0)201 723 2219  
Email: [bastian.vontresckow@uk-essen.de](mailto:bastian.vontresckow@uk-essen.de)

Deputy Director, Department of Hematology and Stem Cell Transplantation,  
permanent position  
Professor (W2) of Clinical and Experimental Hematology  
Lead of University Hospital Essen CAR-T and Lymphoma program  
Married, 3 children

---

### **Academic education and degrees**

1998–2005 Medical School, University of Heidelberg, University of Cologne, University of Nice

### **Scientific degrees**

2001–2005 MD thesis (*summa cum laude*), Department of Internal Medicine I, University Hospital Cologne, Advisor: Prof. Dr. A. Engert  
2015 Postdoctoral lecture qualification (*Habilitation*) in Internal Medicine, University of Cologne  
since 2022 Professor (W2) of Clinical and Experimental Hematology, Department of Hematology and Stem Cell Transplantation, University Duisburg-Essen

### **Professional career from graduation**

2020-ongoing Deputy Director, Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Germany  
2018–2020 Attending physician (Oberarzt), Department of Internal Medicine I, University Hospital Cologne  
2012–2018 Medical head and quality management representative of the clinical trial unit Department of Internal Medicine I, University Hospital Cologne  
2013 Gerok clinician-scientist rotation position, Department of Internal Medicine I, University Hospital Cologne  
since 2012 Editor of the Cochrane Haematological Malignancies Group (CHMG) / Cochrane Haematology  
2011 Board certification as specialist in internal medicine and hematology and oncology  
since 2005 Study physician of the German Hodgkin Study Group (GHSG)  
2005–2007 Grant of the *Köln Fortune* Program, Postdoctoral Research Fellow University of Cologne (Prof. A. Engert)

### **Service to the scientific community**

1. Reviewer for international journals including *Annals of Oncology*, *Blood*, *Lancet Oncology*, *Lancet Haematology*, *Leukemia*, *Journal of Nuclear Medicine* and others; EHA2022 Congress coordinating abstract reviewer Hodgkin Lymphoma; DGHO congress program coordinator Hodgkin Lymphoma 2021-2023
2. Editor and Reviewer Cochrane Haematology
3. 2013-2022 Lecturer in the Certificate of Competence in Lymphoma, European School of Oncology (ESO) and Ulm University (e-Learning), ESCO faculty member

4. Contribution to several national guidelines (S3 guidelines Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma) and EHA-ESMO guideline for HIV-associated Lymphoma
5. Invited member of scientific advisory boards of Allogene, Amgen, BMS/Celgene, Cerus, Gilead Kite, Incyte, IQVIA, Lilly, Merck Sharp & Dohme, Miltenyi, Novartis, Noscendo, Pentixapharm, Pfizer, Pierre Fabre, Qualworld, Roche, Sobi and Takeda.

### Memberships

1. Walter-Siegenthaler-Gesellschaft; Member of the Scientific Advisory Board
2. American Society of Hematology (ASH)
3. Deutsche Hodgkin Studiengruppe (German Hodgkin Study Group, GHSG)
4. Cochrane Haematology
5. Deutsche Gesellschaft für Innere Medizin (DGIM)
6. European Hematology Association (EHA)
7. German Lymphoma Alliance (GLA, founding member)
8. Deutscher Hochschulverband (DHV)
9. Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e. V. (DGHO)

### Publications (10 most important)

1: Heger J-M, Mattlener J, Schneider J, Gödel P, Sieg N, Ullrich F, Lewis R, Bucaciuc-Mracica T, Schwarz RF, Rueß D, Ruge MI, Montesinos-Rongen M, Deckert M, Blau T, Kutsch N, Balke-Want H, Weiss J, Becker K, Reinhardt HC, Hallek M, Borchmann P, **von Tresckow B\***, Borchmann S\*. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA. **Blood**. **2023** in press. \* equal contribution

2: Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, **von Tresckow B**. Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. **J Clin Oncol**. **2022** Dec 12;JCO2202355. doi: 10.1200/JCO.22.02355. Epub ahead of print. PMID: 36508302.

3: Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, **von Tresckow B**, Ayuk F, Wagner-Drouet EM, Wulf GG, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, Fante MA, Schroers R, Bayir L, Borchmann P, Buecklein V, Hasenkamp J, Hanoun C, Thomas S, Beelen DW, Lengerke C, Kroeger N, Dreger P. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. **Blood**. **2022** Jul 28;140(4):349-358. doi: 10.1182/blood.2021015209. PMID: 35316325.

4: Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, **von Tresckow B**, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. **Nat Med**. **2022** Feb;28(2):325-332. doi: 10.1038/s41591-021-01622-0. Epub 2021 Dec 17. PMID: 34921238.

5: Bröckelmann PJ, Müller H, Gillessen S, Yang X, Koeppel L, Pilz V, Marinello

P, Kaskel P, Raut M, Fuchs M, Borchmann P, Engert A, **von Tresckow B**. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. **Leukemia**. **2022** Mar;36(3):772-780. doi: 10.1038/s41375-021-01442-8. Epub 2021 Oct 9. PMID: 34628472; PMCID: PMC8885415.

6: Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, Diehl V, Borchmann P, Engert A, **von Tresckow B**. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). **Lancet Haematol**. **2021** Apr;8(4):e278-e288. doi: 10.1016/S2352-3026(21)00029-6. PMID: 33770483.

7: **von Tresckow B\***, Kreissl S\*, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. **Lancet Haematol**. **2018** Oct;5(10):e462-e473. doi: 10.1016/S2352-3026(18)30140-6. PMID: 30290903. \*equal contribution

8: Sasse S, Goergen H, Plütschow A, Böll B, Eichenauer DA, Fuchs M, Behringer K, Zijlstra JM, Greil R, Markova J, Topp MS, Meissner J, Neubauer A, Baues C, Engert A, Borchmann P, **von Tresckow B**. Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. **J Clin Oncol**. **2018** Sep 1;36(25):2603-2611. doi: 10.1200/JCO.2018.78.7192. Epub 2018 Jul 10. PMID: 29989855.

9: Haverkamp H, Böll B, Eichenauer DA, Sasse S, Fuchs M, Borchmann P, Diehl V, Engert A, **von Tresckow B**. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials. **J Clin Oncol**. **2015** Aug 1;33(22):2430-6. doi: 10.1200/JCO.2014.60.4264. Epub 2015 Jun 22. PMID: 26101245.

10: **von Tresckow B**, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. **J Clin Oncol**. **2012** Mar 20;30(9):907-13. doi: 10.1200/JCO.2011.38.5807. Epub 2012 Jan 23. PMID: 22271480.